NICE has recommended teplizumab for NHS use — the first treatment to delay the onset of symptomatic type 1 diabetes by an average of nearly three years. In this episode, we speak to Lucy Chambers, Head of Research Impact and Communications at Diabetes UK, and Amy Norman, whose daughter Imogen accessed teplizumab through a managed access programme after being identified through the ELSA screening study. Our NICE talks podcasts are availableon a variety of different platforms.
UK NICE
NICE recommends teplizumab for NHS use to delay type 1 diabetes onset
Original title: Changing the course: the NHS's first treatment to delay type 1 diabetes
NICE has recommended teplizumab for NHS use as the first treatment to delay symptomatic type 1 diabetes onset by approximately three years.
Published by UK NICE. HealthSignal links to the original document; the summary above is extracted from the source text.